[Latest] Global Neoantigen Cancer Vaccine Market Size/Share Worth USD 1.98 Billion by 2034 at a 15.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 10, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product (Personalised antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034“ in its research database.

“According to the latest research study, the demand of global Neoantigen Cancer Vaccine Market size & share was valued at approximately USD 0.49 Billion in 2024 and is expected to reach USD 0.55 Billion in 2025 and is expected to reach a value of around USD 1.98 Billion by 2034, at a compound annual growth rate (CAGR) of about 15.2% during the forecast period 2025 to 2034.”

Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=70350

Neoantigen Cancer Vaccine Market Overview

As per the industry experts at CMI, the Neoantigen Cancer Vaccine Market is quickly growing as a result of the significance placed on personalized cancer therapies. The leading companies include OSE Immunotherapeutic SA, Gritstone Bio Inc., BioNTech SE, Hoffmann-La Roche Ltd and Pfizer Inc., all of whom are developing individualized cancer vaccines targeting patient-specific tumor neoantigens to enhance the immune response. Various malignancies are receiving these vaccines to enhance their outcomes.

Governments are supporting clinical trials and exploring fast-track CRA regulatory approvals to help accelerate the process and innovations. The pharma, biotechnology, and research community continue driving collaborations to advance cancer vaccines. Investment funding is increasing in the neoantigen cancer vaccine products globally—North America, Europe and Asia- pacific are the top three regions. This experience will add a new wave of molecularly-targeted and precisely effective cancer immunotherapies to the suite of effective pharmaceutical therapies worldwide.

Neoantigen Cancer Vaccine Market Growth Factors and Dynamics

• Increasing incidence of cancer: The increasing incidence of cancer worldwide is a driving force behind the growth of the neoantigen cancer vaccine market. The increasing incidence of cancer creates a large demand for innovative, personalized therapies. Neoantigen vaccines designed to target mutations unique to an individual’s tumor provide a breaking point in addressing multiple cancers effectively. The recent, notable positive Phase 2 results by BioNTech for its mRNA immunotherapy candidate BNT111 in patients with advanced melanoma in 2024 illustrate a greater focus on personalized cancer therapies. Furthermore, the increasing incidence of cancer diagnoses shown by the U.S. National Cancer Institute provides a pertinent need for advanced therapies like neoantigen vaccines.

• Advances in delivery systems: Advances in delivery systems for vaccines, such as lipid nanoparticles and viral vectors, have provided stability, targeting, and greater efficacy regarding neoantigen vaccines, in addition to improving clinical response and efficacy in personalized cancer therapies. Again, the international Phase 3 “Artemia” trial, which was launched by OSE Immunotherapeutics in 2024, is noteworthy. This Phase 3 trial is for Tedopi, an “off-the-shelf” neo-epitope-based cancer vaccine for HLA-A2-positive patients with metastatic non-small cell lung cancer (NSCLC) and lethargy who developed secondary resistance to immune checkpoint inhibitors. This pivotal trial aims to gain regulatory approval for Tedopi. This is a meaningful advancement in the neoantigen vaccine delivery system and cancer treatment.

• Increased cancer incidence: The incidence of cancer worldwide is one of the major factors propelling growth of the neoantigen cancer vaccine market. As pointed out by the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 20 million new cases and 10 million deaths every year. The increasing rates of cancer demand new, more effective, and targeted treatments other than the traditional ones of chemotherapy and radiation. Neoantigen cancer vaccines are unique and extremely specific personalized therapies that stimulate the immune system to identify and attack cancer cells ‘with laser precision’, without employing belated-acting toxic treatments like chemotherapy and radiation on healthy tissue. The increasing rates of difficult to treat cancers such as melanoma, non-small cell lung cancer, and particularly glioblastoma hold potential for these types of precision-based immunotherapy.

Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ https://www.custommarketinsights.com/request-for-customization/?reportid=70350

• Advancements in Immunotherapy: Recent breakthroughs in immunotherapy have significantly contributed to the emergence and expansion of the neoantigen cancer vaccine market. Immunotherapy has revolutionized oncology by offering treatments that harness the body’s immune system to target and eliminate cancer cells. Among these, neoantigen vaccines represent a cutting-edge class of therapies that are personalized based on tumor-specific mutations, making them uniquely suited for individualized treatment strategies. Innovations such as checkpoint inhibitors, CAR-T cells, and adoptive T-cell therapies have validated the immune system’s potential in combating cancer, laying the groundwork for further development of neoantigen approaches. Additionally, the integration of advanced computational biology and next-generation sequencing technologies enables rapid identification and synthesis of neoantigens, accelerating vaccine production timelines and improving therapeutic outcomes. These technological advancements are critical in transforming experimental treatments into viable commercial products.

Report Scope